Disney: The Media Juggernaut Continues Hot Streak

Noah Kiedrowski - INO.com Contributor - Biotech


The Media Juggernaut

I’ve been a long bull of The Walt Disney Company (NYSE:DIS) stock, particularly since the post-ESPN induced sell-off in throughout 2016. Since the lows of October 2016, Disney has seen a huge appreciation in stock price, breaking out to above $115 per share level as of late. This upswing has been on the heels of multiple catalysts such as of reporting record annual results, breaking the all-time worldwide box-office record, witnessing a slew of analyst upgrades, Iger extending his contract as CEO, ESPN woes subsiding, Shanghai Disney opening and Disney’s movie line-up announced through 2020. This inflection point coincided with Doctor Strange, Moana and Star Wars Rouge One in Q4 of 2016 followed by a record opening for its live action film, Beauty and the Beast. The stock fell from the $120s in late 2015 to the high $80s and had been stuck in the $80-$90 range all throughout 2016. This perpetual slump was almost entirely attributable to the decrease in ESPN subscribers and subsequent revenue and profit declines from that franchise. The ESPN franchise within the Media Networks segment generates revenue/operating income that is disproportionate to the amount of the company’s overall revenue and operating profit. Thus, one can see why investors were spooked after consecutive significant declines in ESPN subscribers and thus financial numbers over the past three years. Excluding ESPN, Disney has been executing well and reporting record numbers throughout all of its other business segments. Disney has a deep and diversified enough entertainment portfolio that made a compelling case that these ESPN fears were being overblown. Disney offered and still offers a compelling long-term investment opportunity considering the growth, pipeline, diversity of its portfolio, share repurchase program and dividend. Continue reading "Disney: The Media Juggernaut Continues Hot Streak"

Immunotherapy Showing Potential Promise - Immunotherapy ETF

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

Immunotherapy has emerged as a new potential frontier in treating a variety of diseases. Immunotherapy has risen to national attention via being showcased on the front cover of Time magazine in 2016 (Figure 1). Now, immunotherapy has been thrust into the forefront as an emerging and exciting therapeutic area that has experienced massive growth in terms of potential pipeline candidates across all capitalization biotech companies. Immunotherapy ushers in a new class of potentially promising therapies by harnessing the body’s immune system to recognize and eradicate debilitating diseases, specifically cancer and chronic viral infections. This immunotherapy approach may inevitably result in a paradigm shift from traditional medical intervention. Immunotherapy possesses holistic attributes by harnessing the body’s immune system to contend with or in some cases prevent disease. In addition to the holistic aspects, immunotherapy has been shown to have a favorable side effect profile and best-in-class efficacy across many different disease states. These therapies may provide a powerful technology to contend with a host of diseases, and in a future state, may potentially serve as a preventative technology similar to a traditional vaccine. Immunotherapy has evolved into many different classifications with differing modalities over the past several years, which has given rise to a growing number mid and small-cap biotechnology companies with potential investment opportunities via an immunotherapy ETF. In late 2015,Loncar Cancer Immunotherapy launched the Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) and provided investors with an opportunity to invest in this unique cohort.

Time Magazine Immunotherapy Cover
Figure 1 - TIME magazine cover showcasing immunotherapy and its potential in treating disease

Continue reading "Immunotherapy Showing Potential Promise - Immunotherapy ETF"

Disney Continues To Deliver - Iger Extends Contract

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

Over the previous six months, The Walt Disney Company (NYSE:DIS) has logged a solid 22% gain, moving from ~$92 to ~$113. I’ve been long Disney and wrote several pieces on how the strong fundamentals made a compelling case to buy shares when the stock traded down into the low $90s. The compelling long-term investment opportunity was drawn considering the growth drivers, pipeline, diversity of its portfolio, share repurchase program and dividend. As the first quarter of 2017 comes to an end, Disney continues to deliver strong fundamentals and catalysts moving into the future. At a high-level, Disney’s board has decided to extend Bob Iger’s contract to remain CEO, direct-to-consumer ESPN offerings are in the works, analyst upgrades continue to be issued and Beauty and Beast delivered record breaking numbers to start its film release slate on a strong note for 2017 (Figure 1).

NYSE:DIS
Figure 1 – Six-Month Chart For Disney

Bob Iger Extends Contract

Disney’s Board of Directors announced that it had extended Bob Iger’s contract as Chairman and Chief Executive Officer to July 2, 2019. Bob Iger had been the subject of increasing succession talk after the lead candidate to replace Iger as CEO, Tom Staggs went on to pursue other opportunities and left the company last year. Continue reading "Disney Continues To Deliver - Iger Extends Contract"

Issue #13: Icahn's Bristol-Myers Stake, Biotech Cohort Rallies and Eli Lilly's CEO Speaks

INO Health & Biotech Stock Guide

Issue #13

BIOTECH, HEALTH & PHARMA NEWS

Ever since President Trump met with a group of pharmaceutical executives at the White House, the entire biotech cohort has witnessed a resurgence as of late. This meeting was perceived as a positive interaction between the nascent government and the industry on a whole. This coincides with a consortium of big pharma companies joining forces to address transparency on drug price increases. Allergan (AGN), J&J (JNJ), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) have committed to limiting any annual drug pricing increases to less than 10%. J&J, AbbVie and Merck all published annual reports regarding its portfolio and the price increases they’ve implemented. This transparency coalition is a step in the right direction to appease the general public and governmental officials that have been very critical of drug price increases. To add icing on the cake, Amgen’s CEO stated “We look forward to working collaboratively with the new administration.” Pharmaceutical executives are being proactive to be part of the conversation and be present at the table when it comes to working with Trump and his hardline stance regarding jobs and drug prices. The collaborative approach will hopefully bode well for the industry as a healthy relationship is fostered perceived on Wall Street.

Continue reading "Issue #13: Icahn's Bristol-Myers Stake, Biotech Cohort Rallies and Eli Lilly's CEO Speaks"